Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Research Report 2023

Publication ID:

PB504244487

Publication Date:

May 10, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Nucleic acid diagnosis is a method of diagnosis of human body state and disease by using the theory and technology of molecular biology to directly investigate the existence state or defect of nucleic acid, analyze the function of nucleic acid from the nucleic acid structure, replication, transcription or translation level.Its target molecule is DNA or RNA, which reflects the structure and function of nucleic acids.The genes tested are endogenous (that is, the body's own genes) and exogenous (such as viruses, bacteria, etc.), the former is used to diagnose whether the gene has disease, the latter is used to diagnose whether there is pathogen infection.
Highlights
The global Nucleic Acid鈥揃ased Diagnostic market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nucleic Acid鈥揃ased Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Nucleic Acid鈥揃ased Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Nucleic Acid鈥揃ased Diagnostic in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Nucleic Acid鈥揃ased Diagnostic include Agilent Technologies, Danaher Corporation, Abbott Laboratories, BD, Bio-Rad Laboratories, Roche, Illumina, Inc, Thermo Fisher Scientific Inc. and Merck KGaA, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid鈥揃ased Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid鈥揃ased Diagnostic.
The Nucleic Acid鈥揃ased Diagnostic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nucleic Acid鈥揃ased Diagnostic market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid鈥揃ased Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Agilent Technologies
Danaher Corporation
Abbott Laboratories
BD
Bio-Rad Laboratories
Roche
Illumina, Inc
Thermo Fisher Scientific Inc.
Merck KGaA
Qiagen
Segment by Type
Nucleic Acid Molecular Hybridization
Polymerase Chain Reaction
Thermostatic Amplification
Gene Sequencing
Biochip Technology
Segment by Application
Hospital
Clinical Laboratory
Research Institutions
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid鈥揃ased Diagnostic companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Nucleic Acid Molecular Hybridization
1.2.3 Polymerase Chain Reaction
1.2.4 Thermostatic Amplification
1.2.5 Gene Sequencing
1.2.6 Biochip Technology
1.3 麻豆原创 by Application
1.3.1 Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinical Laboratory
1.3.4 Research Institutions
1.3.5 Clinic
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Perspective (2018-2029)
2.2 Nucleic Acid鈥揃ased Diagnostic Growth Trends by Region
2.2.1 Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nucleic Acid鈥揃ased Diagnostic Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Nucleic Acid鈥揃ased Diagnostic Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Dynamics
2.3.1 Nucleic Acid鈥揃ased Diagnostic Industry Trends
2.3.2 Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Drivers
2.3.3 Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Challenges
2.3.4 Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid鈥揃ased Diagnostic Players by Revenue
3.1.1 Global Top Nucleic Acid鈥揃ased Diagnostic Players by Revenue (2018-2023)
3.1.2 Global Nucleic Acid鈥揃ased Diagnostic Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid鈥揃ased Diagnostic Revenue
3.4 Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Concentration Ratio
3.4.1 Global Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid鈥揃ased Diagnostic Revenue in 2022
3.5 Nucleic Acid鈥揃ased Diagnostic Key Players Head office and Area Served
3.6 Key Players Nucleic Acid鈥揃ased Diagnostic Product Solution and Service
3.7 Date of Enter into Nucleic Acid鈥揃ased Diagnostic 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid鈥揃ased Diagnostic Breakdown Data by Type
4.1 Global Nucleic Acid鈥揃ased Diagnostic Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Nucleic Acid鈥揃ased Diagnostic Forecasted 麻豆原创 Size by Type (2024-2029)
5 Nucleic Acid鈥揃ased Diagnostic Breakdown Data by Application
5.1 Global Nucleic Acid鈥揃ased Diagnostic Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Nucleic Acid鈥揃ased Diagnostic Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size (2018-2029)
6.2 North America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2018-2023)
6.4 North America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size (2018-2029)
7.2 Europe Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2018-2023)
7.4 Europe Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size (2018-2029)
9.2 Latin America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Nucleic Acid鈥揃ased Diagnostic 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Detail
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Nucleic Acid鈥揃ased Diagnostic Introduction
11.1.4 Agilent Technologies Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.1.5 Agilent Technologies Recent Development
11.2 Danaher Corporation
11.2.1 Danaher Corporation Company Detail
11.2.2 Danaher Corporation Business Overview
11.2.3 Danaher Corporation Nucleic Acid鈥揃ased Diagnostic Introduction
11.2.4 Danaher Corporation Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.2.5 Danaher Corporation Recent Development
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Company Detail
11.3.2 Abbott Laboratories Business Overview
11.3.3 Abbott Laboratories Nucleic Acid鈥揃ased Diagnostic Introduction
11.3.4 Abbott Laboratories Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.3.5 Abbott Laboratories Recent Development
11.4 BD
11.4.1 BD Company Detail
11.4.2 BD Business Overview
11.4.3 BD Nucleic Acid鈥揃ased Diagnostic Introduction
11.4.4 BD Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.4.5 BD Recent Development
11.5 Bio-Rad Laboratories
11.5.1 Bio-Rad Laboratories Company Detail
11.5.2 Bio-Rad Laboratories Business Overview
11.5.3 Bio-Rad Laboratories Nucleic Acid鈥揃ased Diagnostic Introduction
11.5.4 Bio-Rad Laboratories Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.5.5 Bio-Rad Laboratories Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Nucleic Acid鈥揃ased Diagnostic Introduction
11.6.4 Roche Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.6.5 Roche Recent Development
11.7 Illumina, Inc
11.7.1 Illumina, Inc Company Detail
11.7.2 Illumina, Inc Business Overview
11.7.3 Illumina, Inc Nucleic Acid鈥揃ased Diagnostic Introduction
11.7.4 Illumina, Inc Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.7.5 Illumina, Inc Recent Development
11.8 Thermo Fisher Scientific Inc.
11.8.1 Thermo Fisher Scientific Inc. Company Detail
11.8.2 Thermo Fisher Scientific Inc. Business Overview
11.8.3 Thermo Fisher Scientific Inc. Nucleic Acid鈥揃ased Diagnostic Introduction
11.8.4 Thermo Fisher Scientific Inc. Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.8.5 Thermo Fisher Scientific Inc. Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Detail
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Nucleic Acid鈥揃ased Diagnostic Introduction
11.9.4 Merck KGaA Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.9.5 Merck KGaA Recent Development
11.10 Qiagen
11.10.1 Qiagen Company Detail
11.10.2 Qiagen Business Overview
11.10.3 Qiagen Nucleic Acid鈥揃ased Diagnostic Introduction
11.10.4 Qiagen Revenue in Nucleic Acid鈥揃ased Diagnostic Business (2018-2023)
11.10.5 Qiagen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Agilent Technologies
Danaher Corporation
Abbott Laboratories
BD
Bio-Rad Laboratories
Roche
Illumina, Inc
Thermo Fisher Scientific Inc.
Merck KGaA
Qiagen

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.